Limits...
Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Mora J, Alaminos M, de Torres C, Illei P, Qin J, Cheung NK, Gerald WL - Br. J. Cancer (2004)

Bottom Line: A significantly better overall and progression-free survival was detected in stage 4 patients displaying 9p21-23 LOH.The only well-characterised transcript among them was nuclear factor I-B3.Our results suggest a role for genes located telomeric of 9p21 in good risk NB.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. jmora@hsjdbcn.org

ABSTRACT
Chromosome 9p21 is frequently deleted in many cancers. Previous reports have indicated that 9p21 LOH is an uncommon finding in neuroblastoma (NB), a tumour of childhood. We have performed an extensive analysis of 9p21 and genes located in this region (cyclin-dependent kinase inhibitor 2A - CDKN2A/p16(INK4a), CDKN2A/p14(ARF), CDKN2B/p15(INK4b), MTAP, interferon alpha and beta cluster). LOH was detected in 16.4% of 177 NB. The SRO was identified between markers D9S1751 and D9S254, at 9p21-23, a region telomeric to the CDKN2A and MTAP genes. A significantly better overall and progression-free survival was detected in stage 4 patients displaying 9p21-23 LOH. Hemizygous deletion of the region harbouring the CDKN2A and CDKN2B loci was identified in two tumours by means of fluorescent in situ hybridisation and MTAP was present by immunostaining in all but one tumour analysed. The transcriptional profile of tumours with 9p21-23 LOH was compared to that of NB displaying normal 9p21-23 status by means of oligonucleotide microarrays. Four of the 363 probe sets downregulated in tumours with 9p21-23 LOH were encoded by genes mapping to 9p22-24. The only well-characterised transcript among them was nuclear factor I-B3. Our results suggest a role for genes located telomeric of 9p21 in good risk NB.

Show MeSH

Related in: MedlinePlus

Shortest region of overlap (SRO) at 9p21–23 between markers cent – D9S1751 and D9S254 – pTer, a region telomeric to the CDKN2A and MTAP genes. Nine additional tumours, displaying LOH at a region centromeric to CDKN2A, are not shown. Yellow boxes (−)=loss of heterozygosity. White boxes (+)=retained heterozygosity. (H)=noninformative. (MM)=microsatellite mutation. (AI)=allelic imbalance from a triploid tumour. Blank boxes=not tested.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747697&req=5

fig2: Shortest region of overlap (SRO) at 9p21–23 between markers cent – D9S1751 and D9S254 – pTer, a region telomeric to the CDKN2A and MTAP genes. Nine additional tumours, displaying LOH at a region centromeric to CDKN2A, are not shown. Yellow boxes (−)=loss of heterozygosity. White boxes (+)=retained heterozygosity. (H)=noninformative. (MM)=microsatellite mutation. (AI)=allelic imbalance from a triploid tumour. Blank boxes=not tested.

Mentions: LOH defined as loss of two contiguous microsatellite markers was detected in 29 (16.4%) of the 177 tumours in the first screening. This proportion was higher (22.6%) in favourable nonstage 4 (4s and LR) than in stage 4 tumours (11.7%). Of 29, 20 (68.9%) demonstrated an SRO between markers D9S1751 and D9S254, a region telomeric to the CDKN2A and MTAP genes and near the IFN gene cluster (Figure 2Figure 2


Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Mora J, Alaminos M, de Torres C, Illei P, Qin J, Cheung NK, Gerald WL - Br. J. Cancer (2004)

Shortest region of overlap (SRO) at 9p21–23 between markers cent – D9S1751 and D9S254 – pTer, a region telomeric to the CDKN2A and MTAP genes. Nine additional tumours, displaying LOH at a region centromeric to CDKN2A, are not shown. Yellow boxes (−)=loss of heterozygosity. White boxes (+)=retained heterozygosity. (H)=noninformative. (MM)=microsatellite mutation. (AI)=allelic imbalance from a triploid tumour. Blank boxes=not tested.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747697&req=5

fig2: Shortest region of overlap (SRO) at 9p21–23 between markers cent – D9S1751 and D9S254 – pTer, a region telomeric to the CDKN2A and MTAP genes. Nine additional tumours, displaying LOH at a region centromeric to CDKN2A, are not shown. Yellow boxes (−)=loss of heterozygosity. White boxes (+)=retained heterozygosity. (H)=noninformative. (MM)=microsatellite mutation. (AI)=allelic imbalance from a triploid tumour. Blank boxes=not tested.
Mentions: LOH defined as loss of two contiguous microsatellite markers was detected in 29 (16.4%) of the 177 tumours in the first screening. This proportion was higher (22.6%) in favourable nonstage 4 (4s and LR) than in stage 4 tumours (11.7%). Of 29, 20 (68.9%) demonstrated an SRO between markers D9S1751 and D9S254, a region telomeric to the CDKN2A and MTAP genes and near the IFN gene cluster (Figure 2Figure 2

Bottom Line: A significantly better overall and progression-free survival was detected in stage 4 patients displaying 9p21-23 LOH.The only well-characterised transcript among them was nuclear factor I-B3.Our results suggest a role for genes located telomeric of 9p21 in good risk NB.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. jmora@hsjdbcn.org

ABSTRACT
Chromosome 9p21 is frequently deleted in many cancers. Previous reports have indicated that 9p21 LOH is an uncommon finding in neuroblastoma (NB), a tumour of childhood. We have performed an extensive analysis of 9p21 and genes located in this region (cyclin-dependent kinase inhibitor 2A - CDKN2A/p16(INK4a), CDKN2A/p14(ARF), CDKN2B/p15(INK4b), MTAP, interferon alpha and beta cluster). LOH was detected in 16.4% of 177 NB. The SRO was identified between markers D9S1751 and D9S254, at 9p21-23, a region telomeric to the CDKN2A and MTAP genes. A significantly better overall and progression-free survival was detected in stage 4 patients displaying 9p21-23 LOH. Hemizygous deletion of the region harbouring the CDKN2A and CDKN2B loci was identified in two tumours by means of fluorescent in situ hybridisation and MTAP was present by immunostaining in all but one tumour analysed. The transcriptional profile of tumours with 9p21-23 LOH was compared to that of NB displaying normal 9p21-23 status by means of oligonucleotide microarrays. Four of the 363 probe sets downregulated in tumours with 9p21-23 LOH were encoded by genes mapping to 9p22-24. The only well-characterised transcript among them was nuclear factor I-B3. Our results suggest a role for genes located telomeric of 9p21 in good risk NB.

Show MeSH
Related in: MedlinePlus